Forensic Analysis · Pharmaceuticals & Biotechnology · as of Nov 9, 2026

Biomarin Pharmaceutical Inc (BMRN)

A forensic read on Biomarin Pharmaceutical Inc built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

B · Sound & dependable

Forensic grade

Safe

Financial health

7.4

Distress distance

Clean

Earnings quality

Forensic signals

5.9%

ROE

12.9%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Biomarin Pharmaceutical Inc earns a B (Sound & dependable) forensic quality grade, and its balance-sheet distress test reads 7.4, placing it in the Safe zone. 1 forensic signal was flagged in its latest SEC filings, led by return on invested capital.

What the filings flag

5.4%

FY2025

Return on invested capital. Return on invested capital is 5.4% in the latest fiscal year, against 3.4% in FY2023, having run between 3.4% and 7.4% across FY2023–FY2025 with no direction held. After-tax operating profit was $165M in FY2023 and $296M in FY2025, with operating income at 7.7% of revenue in FY2023, 17.0% in FY2024 and 12.7% in FY2025. The capital base behind it cannot be compared across FY2023–FY2025: short-term debt is tagged in one of those two fiscal years and not the other, and an untagged line enters this calculation as zero, so any change in the base would be a change in what the filer tagged. $729M of the $5.5B base at FY2025 is short-term investments and long-term marketable securities (13.3%) — securities held beside cash, which the base keeps because only cash is subtracted from it; they earn the balance sheet's yield, which is not in the operating profit above, so this rate understates what the operating capital earns. FY2025's operating profit carried a $125M asset write-down that alone took about 1.6 points off that year's return, so the latest return is depressed by that charge. A non-cash write-down lowers the reported return in the year it lands.

Key fundamentals

Latest Revenue$3.22B

Revenue Growth YoY+12.9%

Revenue CAGR (2yr)+15.4%

Net Margin10.8%

Free Cash Flow$725.0M

Return on Equity5.9%

Debt / Equity0.10x

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Biomarin Pharmaceutical Inc's actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Nov 9, 2026. Forensic signals flag probability, not certainty.

See a wrong number? Report an error with the filing it should match.